cagrilintide tirzepatide combination trial clinical Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study Cagrilintide Cagrilintide: The Next-Gen Peptide for

The majority of current GLP-1 users have type 2 diabetes as their primary diagnosis, though a growing proportion are using these medications primarily for chronic weight management

As the most extensively studied GLP-1 receptor agonist in clinical history, semaglutide provides researchers with an unparalleled reference compound for GLP-1 pathway studies

Rodolico for providing Supplementary Table 3

Larger volumes can be slightly more challenging for sublingual administration because there is more liquid to hold in a relatively small space

Injecting at a 90-degree angle with a quick, confident motion, rotating injection sites at least one inch apart, applying cold therapy before injection, and allowing at least two weeks between injections to the same site all reduce bruising